Imperial College London
Portrait Picture

MrPaulRogers

Faculty of Medicine, Department of Infectious Disease

Research Technician
 
 
 
//

Contact

 

+44 (0)20 7594 0977paul.rogers CV

 
 
//

Location

 

258 Shattock Lab.Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Beale:2000:10.1054/bjoc.1999.0939,
author = {Beale, PJ and Rogers, P and Boxall, F and Sharp, SY and Kelland, LR},
doi = {10.1054/bjoc.1999.0939},
journal = {British Journal of Cancer},
pages = {436--440},
title = {BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.},
url = {http://dx.doi.org/10.1054/bjoc.1999.0939},
volume = {82},
year = {2000}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a panel of human ovarian carcinoma xenografts, there was no consistent pattern of BCL-2 expression. Two relatively sensitive lines (A2780 and CH1) have been stably transfected with bcl-2 and bcl(XL) respectively and two relatively resistant lines (A2780cisR and SKOV-3) stably transfected with bax. Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. There was no significant difference in sensitivity of the pair of lines by clonogenic assay. No significant changes in chemosensitivity to a variety of DNA-damaging or tubulin-interactive agents were observed in the remaining transfected lines. Taken together, these results suggest that, in human ovarian carcinoma cells, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs.
AU  - Beale,PJ
AU  - Rogers,P
AU  - Boxall,F
AU  - Sharp,SY
AU  - Kelland,LR
DO  - 10.1054/bjoc.1999.0939
EP  - 440
PY  - 2000///
SN  - 0007-0920
SP  - 436
TI  - BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1054/bjoc.1999.0939
UR  - https://www.ncbi.nlm.nih.gov/pubmed/10646901
UR  - https://www.nature.com/articles/6690939
UR  - http://hdl.handle.net/10044/1/92189
VL  - 82
ER  -
Download